Dermatology News

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.

Nektar Therapeutics has completed target enrollment for its phase 2b study of rezpegaldesleukin for the treatment of patients with moderate to severe atopic dermatitis, the company announced in a press release.

The single-injection 2 mL prefilled syringe and autoinjector for Bimzelx 320 mg is now available, UCB announced in a press release.

New data suggest Restylane Lyft or Contour in combination with Sculptra corrects contour deficiencies in patients experiencing facial volume loss following medication-driven weight loss, according to a Galderma press release.

Requiring erythema alone for entry into cutaneous lupus erythematosus trials may exclude patients with skin of color and increase health disparities, according to a study.

As physicians, we have all borne witness to patients dying at a young age, whether from an unforeseen illness or injury.

Topical ET-02 demonstrated successful results in its first-in-human clinical trial for the treatment of androgenic alopecia, Eirion Therapeutics announced in a press release.

The VISIBLE trial demonstrated that intentional efforts to recruit and retain patients with skin of color result in a speedy enrollment process and diverse patient pool, according to a study.

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating the efficacy of the ointment’s 2% formulation, the company announced in a press release.